Abstract Number: 2305 • ACR Convergence 2024
Anti-Ku Positivity in Primary Sjögren’s Disease Is Associated with a More Systemic Active Disease
Background/Purpose: Sjögren’s disease (SjD) is an autoimmune disease characterized by a wide range of symptoms, and 30% to 60% of patients developed systemic manifestations. The…Abstract Number: 2664 • ACR Convergence 2024
BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease
Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…Abstract Number: 0154 • ACR Convergence 2024
Chronic Sinusitis Predicting Interstitial Lung Disease in Sjögren’s Syndrome: A Comprehensive USA Population Study (2004-2024)
Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disorder primarily affecting the exocrine glands, but it also impacts various parts of the respiratory system, including…Abstract Number: 1412 • ACR Convergence 2024
Survival and Predictive Markers of Prognosis in Patients with Cancer Occurrence After Sjögren Syndrome: A Long-term Observational Study
Background/Purpose: Patients with Sjögren syndrome (SS) have been reported to have a higher risk of cancer than the general population, and malignancy constitutes one of…Abstract Number: 1428 • ACR Convergence 2024
A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren’s Disease Exploring the Novel Composite Endpoint Sjögren’s Tool for Assessing Response (STAR)
Background/Purpose: Two randomized controlled phase 2 trials in patients with active Sjogren’s disease (SjD) were recently completed, the LOUiSSe trial assessing the Bruton Tyrosine kinase…Abstract Number: 2290 • ACR Convergence 2024
Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren’s Syndrome Pathology
Background/Purpose: Primary Sjögren's syndrome (pSS) is characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to functional loss and gradually causing dry mouth…Abstract Number: 2306 • ACR Convergence 2024
Deconstruction and Reconstruction of Sjögren’s Disease: AMP®-AIM Partnership
Background/Purpose: The Accelerating Medicines Partnership (AMP®) is a public-private partnership with the goal of transforming the current model for developing new diagnostics and treatments by…Abstract Number: PP09 • ACR Convergence 2024
Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS
Background/Purpose: Like many suffering from autoimmune diseases, my diagnosis was not straightforward and took nearly 13 years to get answers. I first started experiencing an…Abstract Number: 0443 • ACR Convergence 2024
Significance of anti-Ro52 Antibody in Pregnancy Complicated with Anti-SS-A Antibody Positive Rheumatic Disease Patients
Background/Purpose: Anti-SS-A antibodies are associated with neonatal lupus erythematosus and congenital heart block (CHB). Ro/SS-A autoantigen is comprised of 52kDa Ro (Ro52) and 60kDa Ro…Abstract Number: 1413 • ACR Convergence 2024
Pilot Trial of Ustekinumab for Primary Sjogren’s Syndrome
Background/Purpose: Sjogren’s Syndrome (SS) is a chronic autoimmune disease characterized by keratoconjunctivitis sicca and xerostomia. Currently there is no approved systemic treatment for primary SS. …Abstract Number: 1429 • ACR Convergence 2024
Association of Bone Erosion and Microarchitecture with Disease Activity and Damage in Sjögren’s Disease
Background/Purpose: Sjögren's disease (SjD) is a chronic multisystem autoimmune condition characterized by sicca syndrome and inflammatory arthralgia, more common in women. Bone involvement can result…Abstract Number: 2291 • ACR Convergence 2024
The Relationship of the ESSDAI to Health-Related Quality of Life in People Living with Sjogren’s Disease
Background/Purpose: Historically, Heath Related Quality of Life (HRQL) in Sjogren’s Disease (SjD) has been measured by the EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI), which…Abstract Number: 2307 • ACR Convergence 2024
Deep Spatial Profiling Unveils Dominant Double Negative B Cells in Severe Forms of Sjögren’s Syndrome
Background/Purpose: Imaging mass cytometry (IMC) is a powerful high throughput technique that enables in-situ multiparametric analysis of a single fixed tissue section while preserving spatial…Abstract Number: 0451 • ACR Convergence 2024
Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome
Background/Purpose: SLE, primary Sjögren’s disease (pSjD) and APS are systemic rheumatic diseases (SRD) that mainly affect women of childbearing age and have been associated with…Abstract Number: 1414 • ACR Convergence 2024
Evidence-Based Guidelines for Sjögren’s Disease Peripheral Nervous System Manifestations
Background/Purpose: Peripheral Nervous System (PNS) manifestations occur frequently in Sjögren’s disease and can encompass mononeuropathy, polyneuropathy, and autonomic neuropathy. Guidance is needed for rheumatologists, neurologists,…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 18
- Next Page »